CMG Pharmaceutical will manufacture pet treats and snacks and gradually include pet medications in its portfolio.
The Seoul-based company, part of the CHA Biomedical Group, confirmed to GlobalPETS that it is looking at a “variety of possibilities” with a focus on technology and investments in the pet industry.
AJU Daily reported earlier in the year that the medical company acquired ING Medix, a South Korean animal nutrition supplement maker. According to local media, the company would make use of its own distribution network to market and supply soft, chewy supplements.
In a statement to the press, CMG CEO Lee Ju-hyung said that it completed a hazard analysis procedure and is in the process of constructing smart factories.
He also stated that by 2030 the company aims to post annual sales of ₩50 billion ($38.5M/ €36M) in its pet business.
Pet ownership in the Asian country currently stands at 19.6%, according to a recent report by Statista
The latest articles
Partnership turns sour: Better Choice takes Alphia to court
Florida-based Better Choice started legal proceedings against American pet food manufacturer Alphia less than a year after investment.
Musti: more sales in first quarter of 2024 but facing operating loss
The Nordic pet retailer, which has been recently acquired, admits that the results are lower than expected. GlobalPETS learns more.
UK to simplify pet microchipping data system
The new measures aim to combat theft and streamline the process of reuniting lost animals with their owners.
Weekly newsletter to stay up-to-date
Discover what’s happening in the pet industry. Get the must-read stories and insights in your inbox.